Prognostic Significance of Rising Serum CA-125 Levels Within the Normal Range in Patients With Epithelial Ovarian, Primary Peritoneal, and Tubal Cancers, Who, After Initial Treatment, Had a Complete Clinical Response. Issue 8 (1st October 2012)
- Record Type:
- Journal Article
- Title:
- Prognostic Significance of Rising Serum CA-125 Levels Within the Normal Range in Patients With Epithelial Ovarian, Primary Peritoneal, and Tubal Cancers, Who, After Initial Treatment, Had a Complete Clinical Response. Issue 8 (1st October 2012)
- Main Title:
- Prognostic Significance of Rising Serum CA-125 Levels Within the Normal Range in Patients With Epithelial Ovarian, Primary Peritoneal, and Tubal Cancers, Who, After Initial Treatment, Had a Complete Clinical Response
- Authors:
- Levy, Tally
Weiser, Roi
Boaz, Mona
Shem, Erez Ben
Golan, Abraham
Menczer, Joseph - Abstract:
- Abstract : Objective: This study aimed to assess the ability of 3 criteria of rising CA-125 levels within the reference range to predict recurrence in patients with ovarian, primary peritoneal, and tubal carcinomas after complete clinical response to initial treatment. Material and Methods: Included were patients diagnosed during 1998 to 2008 who fulfilled the following criteria: CA-125 levels of 35 U/mL or greater at diagnosis and recurrence, full primary treatment with a complete clinical and radiographic response, follow-up according to schedule, and at least 2 CA-125 results within the reference range during follow-up. Three criteria of rising CA-125 values within the reference range were used for the prediction of recurrence: (1) an absolute increase of 5 U/mL or higher from the nadir value at completion of chemotherapy, (2) early signal of progressive disease criterion, and (3) a rise to an absolute level of 20 U/mL or greater. Results: Of 82 patients who satisfied study inclusion criteria, 58 (70.7%) had disease recurrence. Early signal of progressive disease and a rise to an absolute level of 20 U/mL or greater were highly statistically significant predictors of disease recurrence (odds ratio, 12.62 [95% confidence interval, 2.71–58.7], P = 0.0012; and odds ratio, 6.7 [95% confidence interval, 2.18–20.54], P = 0.001, respectively) and preceded recurrence by a median of 3 and 3.3 months, respectively. Conclusions: Our data indicate that the early signal of progressiveAbstract : Objective: This study aimed to assess the ability of 3 criteria of rising CA-125 levels within the reference range to predict recurrence in patients with ovarian, primary peritoneal, and tubal carcinomas after complete clinical response to initial treatment. Material and Methods: Included were patients diagnosed during 1998 to 2008 who fulfilled the following criteria: CA-125 levels of 35 U/mL or greater at diagnosis and recurrence, full primary treatment with a complete clinical and radiographic response, follow-up according to schedule, and at least 2 CA-125 results within the reference range during follow-up. Three criteria of rising CA-125 values within the reference range were used for the prediction of recurrence: (1) an absolute increase of 5 U/mL or higher from the nadir value at completion of chemotherapy, (2) early signal of progressive disease criterion, and (3) a rise to an absolute level of 20 U/mL or greater. Results: Of 82 patients who satisfied study inclusion criteria, 58 (70.7%) had disease recurrence. Early signal of progressive disease and a rise to an absolute level of 20 U/mL or greater were highly statistically significant predictors of disease recurrence (odds ratio, 12.62 [95% confidence interval, 2.71–58.7], P = 0.0012; and odds ratio, 6.7 [95% confidence interval, 2.18–20.54], P = 0.001, respectively) and preceded recurrence by a median of 3 and 3.3 months, respectively. Conclusions: Our data indicate that the early signal of progressive disease criterion and a single rise to an absolute level of 20 U/mL or greater within reference limits are highly predictive of clinical recurrence, although the latter is simpler to use. However, whether this is of practical clinical value remains to be proven. … (more)
- Is Part Of:
- International journal of gynecological cancer. Volume 22:Issue 8(2012)
- Journal:
- International journal of gynecological cancer
- Issue:
- Volume 22:Issue 8(2012)
- Issue Display:
- Volume 22, Issue 8 (2012)
- Year:
- 2012
- Volume:
- 22
- Issue:
- 8
- Issue Sort Value:
- 2012-0022-0008-0000
- Page Start:
- 1344
- Page End:
- 1348
- Publication Date:
- 2012-10-01
- Subjects:
- Ovarian -- Primary peritoneal and tubal carcinoma -- Complete clinical response -- Rising CA-125 within reference limits -- Recurrence
Generative organs, Female -- Cancer -- Periodicals
616.99465 - Journal URLs:
- http://journals.lww.com/ijgc/pages/default.aspx ↗
http://www3.interscience.wiley.com/journal/118544021/toc ↗
https://ijgc.bmj.com/ ↗
http://journals.lww.com ↗ - DOI:
- 10.1097/IGC.0b013e3182691254 ↗
- Languages:
- English
- ISSNs:
- 1048-891X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.273500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 18087.xml